LEAN BODY-MASS, BODY-SURFACE AREA AND EPIRUBICIN KINETICS

被引:27
作者
COSOLO, WC
MORGAN, DJ
SEEMAN, E
ZIMET, AS
MCKENDRICK, JJ
ZALCBERG, JR
机构
[1] HEIDELBERG REPATRIAT HOSP,DEPT ONCOL,BANKSIA ST,HEIDELBERG,VIC 3081,AUSTRALIA
[2] VICTORIAN COLL PHARM,DEPT PHARMACEUT,PARKVILLE,VIC 3052,AUSTRALIA
[3] AUSTIN HOSP,DEPT ONCOL,HEIDELBERG,VIC 3084,AUSTRALIA
[4] AUSTIN HOSP,DEPT ENDOCRINOL,HEIDELBERG,VIC 3084,AUSTRALIA
关键词
BODY SURFACE AREA; EPIRUBICIN; LEAN BODY MASS;
D O I
10.1097/00001813-199406000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For a number of cytotoxics, a relationship between efficacy and plasma concentrations has recently been demonstrated. Lean body mass has been demonstrated to be a useful parameter for predicting drug clearance for a number of non-cytotoxic drugs. However, the role of lean body mass in predicting drug clearance for any cytotoxic drug has not been previously reported. Our purpose was to investigate lean body mass as a predictor of epirubicin clearance. Pharmacokinetic studies were performed in 10 patients receiving single agent epirubicin. Although preliminary, this study suggests that lean body should be further evaluated and tested in dose optimization studies.
引用
收藏
页码:293 / 297
页数:5
相关论文
共 21 条
  • [1] CAMAGGI CM, 1988, CANCER CHEMOTH PHARM, V21, P221
  • [2] THE EFFECTS OF DOSE AND ROUTE OF ADMINISTRATION ON THE PHARMACOKINETICS OF GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR
    CEBON, JS
    BURY, RW
    LIESCHKE, GJ
    MORSTYN, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1990, 26 (10) : 1064 - 1069
  • [3] EVALUATION OF INFUSION REGIMENS FOR THIOPENTONE AS A PRIMARY ANESTHETIC AGENT
    CRANKSHAW, DP
    EDWARDS, NE
    BLACKMAN, GL
    BOYD, MD
    CHAN, HNJ
    MORGAN, DJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (05) : 543 - 552
  • [4] AN UPDATED COMPARISON OF DRUG DOSING METHODS .2. THEOPHYLLINE
    ERDMAN, SM
    RODVOLD, KA
    PRYKA, RD
    [J]. CLINICAL PHARMACOKINETICS, 1991, 20 (04) : 280 - 292
  • [5] CLINICAL PHARMACODYNAMICS OF HIGH-DOSE METHOTREXATE IN ACUTE LYMPHOCYTIC-LEUKEMIA - IDENTIFICATION OF A RELATION BETWEEN CONCENTRATION AND EFFECT
    EVANS, WE
    CROM, WR
    ABROMOWITCH, M
    DODGE, R
    LOOK, AT
    BOWMAN, WP
    GEORGE, SL
    PUI, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (08) : 471 - 477
  • [6] EVANS WE, 1990, AM SOC CLIN ONCOL, P268
  • [7] GIBALDI M, 1975, PHARMACOKINETICS
  • [8] HALLYNCK T, 1982, ARCH INT PHARMACOD T, V259, P330
  • [9] SHOULD CLEARANCE BE NORMALIZED TO BODY-SURFACE OR TO LEAN BODY-MASS
    HALLYNCK, TH
    SOEP, HH
    THOMIS, JA
    BOELAERT, J
    DANEELS, R
    DETTLI, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (05) : 523 - 526
  • [10] HALLYNCK TH, 1981, CLIN PHARMACOL THER, V3, P414